PT821960E - Utilizacao de derivados da xantina em combinacao com um derivado 5-isoxazol-4-carboamida e/ou um derivado 2-ciano-3-hidroxi-crotonamida, para a modulacao da apoptose - Google Patents

Utilizacao de derivados da xantina em combinacao com um derivado 5-isoxazol-4-carboamida e/ou um derivado 2-ciano-3-hidroxi-crotonamida, para a modulacao da apoptose

Info

Publication number
PT821960E
PT821960E PT97112939T PT97112939T PT821960E PT 821960 E PT821960 E PT 821960E PT 97112939 T PT97112939 T PT 97112939T PT 97112939 T PT97112939 T PT 97112939T PT 821960 E PT821960 E PT 821960E
Authority
PT
Portugal
Prior art keywords
derivatives
alkyl
carboamide
isoxazol
cyano
Prior art date
Application number
PT97112939T
Other languages
English (en)
Inventor
Stefan Mullner
Claudia Dax Dch
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19640556A external-priority patent/DE19640556A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of PT821960E publication Critical patent/PT821960E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PT97112939T 1996-07-31 1997-07-28 Utilizacao de derivados da xantina em combinacao com um derivado 5-isoxazol-4-carboamida e/ou um derivado 2-ciano-3-hidroxi-crotonamida, para a modulacao da apoptose PT821960E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19630837 1996-07-31
DE19640556A DE19640556A1 (de) 1996-10-01 1996-10-01 Verwendung von Xanthinderivaten zur Modulation der Apoptose

Publications (1)

Publication Number Publication Date
PT821960E true PT821960E (pt) 2003-08-29

Family

ID=26027961

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97112939T PT821960E (pt) 1996-07-31 1997-07-28 Utilizacao de derivados da xantina em combinacao com um derivado 5-isoxazol-4-carboamida e/ou um derivado 2-ciano-3-hidroxi-crotonamida, para a modulacao da apoptose

Country Status (11)

Country Link
US (1) US5856330A (pt)
EP (1) EP0821960B1 (pt)
JP (1) JPH1067662A (pt)
AT (1) ATE236637T1 (pt)
AU (1) AU718237B2 (pt)
CA (1) CA2212205C (pt)
DE (1) DE59709755D1 (pt)
DK (1) DK0821960T3 (pt)
ES (1) ES2191794T3 (pt)
MX (1) MX9705771A (pt)
PT (1) PT821960E (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
DE19860802A1 (de) * 1998-12-30 2000-10-26 Virgene Pharmaceuticals Ag Herstellung eines Mittels gegen Hepatitis B-, HI-, Paramyxo und Orthomyxo-Viren
US6458930B1 (en) 2000-11-28 2002-10-01 Cytokinetics, Inc. Aspergillus fumigatus cofilin
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
FR2825928B1 (fr) * 2001-06-18 2004-04-02 Ecole Norm Superieure Cachan Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat polymerisation de l'actine
CA2439471A1 (en) 2001-12-28 2003-07-17 Daiichi Suntory Pharma Co., Ltd. Promoters of the growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors
DE10217254A1 (de) * 2002-04-15 2003-10-23 Proteosys Ag Verwendung von Substanzen zur Behandlung von Tumoren
GB0224014D0 (en) * 2002-10-15 2002-11-27 Oxford Glycosciences Uk Ltd A protein involved in therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737433A (en) * 1964-09-05 1973-06-05 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines
DE2335170C2 (de) * 1973-07-11 1989-07-20 Hoechst Ag, 6230 Frankfurt 1,3-Dialkyl-7-(hydroxyalkyl)-xanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE3508097A1 (de) * 1984-07-21 1986-02-06 Hoechst Ag, 6230 Frankfurt Kombinationspraeparat aus xanthinderivaten und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
IL100536A (en) * 1986-12-31 1994-05-30 Hoechst Roussel Pharma Pharmaceutical preparations containing a history of xanthine Stopping an immune response and relieving adverse conditions resulting from intracellular intervention in an immune response
IL99811A (en) * 1990-10-30 1996-03-31 Roussel Uclaf 3-Cycloalkyl-propanamides, tautomeric forms of these, their salts, method of preparation, use as drugs and preparations containing them
AU9084991A (en) * 1990-11-01 1992-05-26 Board Of Regents, The University Of Texas System Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues
DE59207086D1 (de) * 1991-05-23 1996-10-17 Hoechst Ag Die Verwendung von 1-(5-Oxohexyl)-3-methyl-7-n-propyl-xanthin in der Gefässchirurgie
WO1992021344A2 (en) * 1991-05-24 1992-12-10 Fred Hutchinson Cancer Research Center Modulation of cellular response to external stimuli
MX9203323A (es) * 1991-07-11 1994-07-29 Hoechst Ag El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales.
TW209834B (pt) * 1991-12-11 1993-07-21 Hoechst Ag
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
DE59304710D1 (de) * 1992-02-22 1997-01-23 Hoechst Ag Verwendung von Xanthinderivaten zur Behandlung von Muskelschädigungen nach vollständiger Unterbrechung der Blutzirkulation
US5763446A (en) * 1992-03-26 1998-06-09 University Of Southern California Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases
GB9321083D0 (en) * 1993-10-13 1993-12-01 Univ Mcgill Phosphatase inhibitors in channel diseases
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
WO1996005836A2 (en) * 1994-08-25 1996-02-29 Medical University Of South Carolina Methods of treating cold symptoms using pentoxifylline
ATE303994T1 (de) * 1994-12-29 2005-09-15 Univ California Verbindungen für ceramid-vermittelter signalübertragung

Also Published As

Publication number Publication date
JPH1067662A (ja) 1998-03-10
AU3236797A (en) 1998-02-05
CA2212205A1 (en) 1998-01-31
US5856330A (en) 1999-01-05
DE59709755D1 (de) 2003-05-15
ATE236637T1 (de) 2003-04-15
AU718237B2 (en) 2000-04-13
DK0821960T3 (da) 2003-07-21
EP0821960B1 (de) 2003-04-09
CA2212205C (en) 2007-12-04
MX9705771A (es) 1998-08-30
EP0821960A1 (de) 1998-02-04
ES2191794T3 (es) 2003-09-16

Similar Documents

Publication Publication Date Title
DE59611022D1 (de) Zubereitung, enthaltend Lipoproteine und Crotonsäureamidderivate
GR3023603T3 (en) Methods for treating per-menopausal syndrome.
HUP0000610A2 (hu) Fájdalomcsillapító hatású piperidinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
DZ1934A1 (fr) Dérivés de cycloalcanoindoles et de cycloalcanoazaindoles.
PT821960E (pt) Utilizacao de derivados da xantina em combinacao com um derivado 5-isoxazol-4-carboamida e/ou um derivado 2-ciano-3-hidroxi-crotonamida, para a modulacao da apoptose
EG19884A (en) Morpholinourea derivatives
AU3236897A (en) Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
DK0769296T3 (da) Anvendelse af et natrium- eller lysiniumsalt af crotonsyreamidderivater til fremstilling af et lægemiddel til behandling af cancer
UA41928C2 (uk) Похідні оксазолідину, спосіб їх одержання, фармацевтична композиція та спосіб її одержання, спосіб лікування захворювань
NZ286756A (en) Indole, indazole, and benzisoxazole derivatives substituted in position 3' by 4-benzoylperhydroazepin-1-ylalkyl or 3-substituted pyrrolidin-1-ylalkyl
AU3748697A (en) 2-cyano-3, 5-dihydroxyhex-2-enecarboxamide derivatives
DE69810034D1 (de) Disubstituierte trans-3,4,4a,5,6,10b-Hexahydro-2H-napht(1,2-b)-1,4-Oxazine, Verfahren zu deren Herstellung und diese enthaltende pharmazeutigsche Zusammensetzungen
NZ330169A (en) 7-alkylamino-6,7,8,9-tetrahydro-cyclopenta[a]naphthalene derivatives
IL116386A0 (en) Use of 1,2 bridged 1,4 dihydropyridines and process for their prepration